Hysteroscopy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Hysteroscopy is a minimally invasive endoscopic procedure in which a thin, lighted telescopic instrument — the hysteroscope — is introduced through the cervix into the uterine cavity without any external incision. It provides direct visualisation of the endometrial lining, the uterine walls, the tubal ostia, and the cervical canal. Diagnostic hysteroscopy is the gold standard for evaluating abnormal uterine bleeding, recurrent miscarriage, and infertility of uterine origin, surpassing transvaginal ultrasound in its ability to detect and characterise intrauterine pathology.

Operative hysteroscopy extends this diagnostic platform into a therapeutic modality. Instruments passed through the working channel of the hysteroscope allow surgeons to resect polyps, submucous fibroids (FIGO types 0, 1, and 2), intrauterine adhesions (Asherman syndrome), and uterine septa — all without abdominal incisions. Fluid distension media (normal saline or glycine) are used to expand the uterine cavity and improve visualisation. Modern hysteroscopes range from 2.9 mm (office-based) to 9 mm (resectoscopes), allowing the procedure to be adapted to the patient's anatomy and operative requirements.

Internationally, hysteroscopy is one of the most commonly performed gynaecological procedures. The global shift toward office hysteroscopy — performed without general anaesthesia using a 'see-and-treat' approach — has significantly reduced costs, improved access, and eliminated surgical waiting times for straightforward cases. For more complex pathology, operative hysteroscopy in an accredited hospital setting under regional or general anaesthesia remains the standard of care.

Hysteroscopy is indicated for the diagnosis and/or treatment of the following conditions:

• Abnormal uterine bleeding (AUB): Heavy menstrual bleeding, intermenstrual bleeding, post-menopausal bleeding — identifying endometrial polyps, fibroids, hyperplasia, or malignancy.
• Endometrial polyps: Targeted polypectomy under direct visualisation; near-complete eradication of identified polyps with a single procedure.
• Submucous uterine fibroids: Hysteroscopic myomectomy for FIGO type 0, 1, and select type 2 fibroids affecting the uterine cavity.
• Intrauterine adhesions (Asherman syndrome): Adhesiolysis to restore the uterine cavity in women with secondary amenorrhoea or infertility.
• Uterine septa: Metroplasty (septum resection) to correct congenital uterine anomalies associated with recurrent miscarriage.
• Retained products of conception: Surgical removal of retained placental tissue after miscarriage, termination, or delivery.
• Endometrial ablation: Destruction of the endometrial lining for treatment of menorrhagia in women who have completed childbearing.
• Lost intrauterine device (IUD): Retrieval of missing or embedded IUDs under direct visualisation.
• Endometrial biopsy: Targeted sampling of suspicious endometrial areas for histopathological analysis.

Ideal candidates for hysteroscopy include:

• Women with unexplained abnormal uterine bleeding that has not resolved with medical therapy.
• Women with recurrent miscarriage (two or more) in whom a uterine structural cause is suspected.
• Women undergoing evaluation for infertility prior to IVF or other assisted reproduction techniques.
• Post-menopausal women with thickened endometrium (>4 mm) on transvaginal ultrasound requiring histological characterisation.
• Women with confirmed submucous fibroids or endometrial polyps on imaging who are symptomatic or planning pregnancy.

Contraindications include:

• Active pelvic inflammatory disease or acute cervicitis — procedure is deferred until infection is eradicated.
• Current pregnancy (except in rare life-saving circumstances).
• Known or suspected cervical or endometrial carcinoma where hysteroscopy might theoretically seed malignant cells (relative contraindication; specialist assessment required).
• Severe medical comorbidities precluding anaesthesia (for operative cases).
• Cervical stenosis that cannot be safely dilated (relative; specialist experience required).

Hysteroscopy encompasses a spectrum of procedures from office-based diagnostics to complex operative interventions:

• Diagnostic office hysteroscopy (no anaesthesia or local only): Using a 2.9–4 mm continuous-flow hysteroscope, the uterine cavity is systematically inspected. Biopsy forceps can be introduced for directed endometrial sampling. Procedure time: 5–15 minutes. Patient returns home immediately.
• Operative hysteroscopy — polypectomy: Mechanical or bipolar energy instruments resect endometrial polyps under direct vision. 90–95% complete removal in a single session. Most cases are outpatient under sedation.
• Hysteroscopic myomectomy: A resectoscope with monopolar or bipolar electrosurgical loop removes submucous fibroids. Type 0 fibroids are removed in one session; type 1 and 2 may require two staged procedures. Duration: 30–60 minutes.
• Adhesiolysis (Asherman syndrome): Intrauterine adhesions are divided under direct vision using scissors, bipolar energy, or laser. Postoperative adjuvant oestrogen therapy and second-look hysteroscopy at 4–8 weeks are standard.
• Endometrial ablation: Second-generation devices (e.g., NovaSure radiofrequency ablation, Thermachoice balloon) destroy the endometrium globally under hysteroscopic guidance in women with menorrhagia who have completed childbearing. Amenorrhoea or hypomenorrhoea is achieved in approximately 80% of patients.
• Hysteroscopic septum resection (metroplasty): Division of a uterine septum using scissors or laser to create a single unified cavity. Associated with significantly improved miscarriage rates post-procedure.

Hysteroscopy offers substantial clinical advantages over alternative diagnostic and therapeutic modalities:

• No incisions: The natural cervical channel is used as the access route, avoiding abdominal incisions and associated wound complications.
• High diagnostic accuracy: Sensitivity of 86–94% and specificity of 90–96% for intrauterine pathology, superior to blind endometrial sampling or transvaginal ultrasound alone.
• Therapeutic in the same session: In most cases, pathology identified at diagnostic hysteroscopy (polyps, small fibroids) can be treated immediately in a 'see-and-treat' approach, avoiding a second anaesthetic.
• Rapid recovery: Most patients resume normal activities within 2–3 days. Return to work is typically possible within 1 week even after operative procedures.
• Improved fertility outcomes: Hysteroscopic polypectomy prior to IVF increases clinical pregnancy rates by approximately 50% compared to IVF without treatment (Bosteels et al., Cochrane 2015). Metroplasty reduces miscarriage rates by 20–30%.
• Preservation of uterus: For women with fibroids or AUB, hysteroscopic treatment avoids hysterectomy in the majority of cases.

Hysteroscopy has a well-established safety record. The overall complication rate for diagnostic hysteroscopy is approximately 0.13%; for operative hysteroscopy it is 0.8–1.5%.

• Uterine perforation: Occurs in 0.4–1% of operative cases. Most perforations are small and managed conservatively; rarely, laparoscopic or laparotomy repair is required.
• Distension media complications (fluid overload or hyponatraemia): Risk with glycine or hypotonic media; modern isotonic saline with strict fluid monitoring has significantly reduced this risk. Incidence: less than 0.2% in experienced hands.
• Haemorrhage: Significant bleeding requiring transfusion occurs in approximately 0.5% of operative cases. Vasopressin injection and bipolar coagulation are available intraoperatively.
• Infection: Post-procedural endometritis occurs in 1–2% of cases. Prophylactic antibiotics (doxycycline) are routinely administered.
• Cervical laceration: Occurs in up to 1% of cases during cervical dilation; managed with direct pressure or a single suture.
• Intrauterine adhesion formation: Following myomectomy or adhesiolysis, new adhesion formation can occur; adjuvant oestrogen therapy and second-look hysteroscopy minimise this risk.
• Air or gas embolism: Extremely rare with modern fluid-based systems; more of a historical concern with CO₂ hysteroscopy.

Immediately post-procedure (Day 0–1): Patients experience mild cramping similar to menstrual discomfort, managed with NSAIDs (ibuprofen 400–600 mg). Light spotting or watery discharge for 1–3 days is expected from the distension media and is normal. Patients undergoing outpatient procedures are discharged within 1–2 hours of recovery.

First week (Days 2–7): Most women return to desk work and light activities within 2–3 days. Strenuous exercise, swimming, and sexual intercourse are avoided for 1 week (diagnostic) or 2–4 weeks (operative). A slight increase in discharge around days 5–10 reflects healing endometrium and resolves spontaneously.

Follow-up appointments: A clinical review at 4–6 weeks is standard after operative hysteroscopy to assess healing and review histopathology results. For adhesiolysis, a second-look hysteroscopy is performed at 4–8 weeks. For endometrial ablation, outcome assessment (menstrual diary) is reviewed at 3 and 6 months.

Reproductive outcomes: Women attempting pregnancy after hysteroscopic treatment (polypectomy, myomectomy, metroplasty) may try to conceive after confirmation of healing — typically 1–2 months post-procedure unless otherwise directed. IVF cycles should not commence until the gynaecologist has confirmed uterine cavity restoration.

Hysteroscopy costs vary significantly based on procedure type (diagnostic vs. operative), country, and facility level. Approximate all-inclusive ranges for operative hysteroscopy at accredited private hospitals:

• India: USD 500–1,500 — large volume of gynaecological cases; experienced surgeons in JCI and NABH-accredited centres.
• Thailand: USD 1,000–2,500 — internationally recognised private hospitals with English-speaking gynaecologists.
• Turkey: USD 800–2,000 — competitive costs; growing gynaecological surgery tourism.
• Malaysia: USD 700–1,800 — KPJ and Pantai group hospitals; short waiting times.
• United Kingdom (private): USD 2,500–5,500 — NHS waiting times for non-urgent hysteroscopy can exceed 12 weeks; private clinics offer faster access.
• United States: USD 3,000–8,000 — without insurance coverage; hospital facility fees dominate cost.

Cost determinants include: diagnostic vs. operative intent, complexity of pathology (polyp vs. fibroid vs. adhesions), anaesthesia type, need for histopathology, inpatient vs. outpatient setting, and surgeon credentials. International patients should budget an additional 5–7 days in-country for pre-operative workup, procedure, and initial recovery before flying.

Depending on the underlying indication, the following alternatives to hysteroscopy may be considered:

• Transvaginal ultrasound (TVUS) with saline infusion sonography (SIS): SIS provides excellent imaging of the uterine cavity but is diagnostic only; pathology identified still requires hysteroscopy for treatment.
• Blind endometrial sampling (Pipelle biopsy): Adequate for excluding endometrial malignancy (sensitivity ~80% for cancer), but misses focal lesions (polyps, focal hyperplasia) that hysteroscopy would detect.
• MRI pelvis: Excellent characterisation of fibroid type and location, particularly for planning preoperative strategy; not therapeutic.
• Medical management of fibroids: GnRH agonists (e.g., leuprolide) or ulipristal acetate can shrink fibroids pre-operatively or as a temporising measure, but are not curative.
• Uterine artery embolisation (UAE): Minimally invasive radiological procedure for multiple or large fibroids; not suitable for submucous type 0 fibroids where hysteroscopy is clearly superior.
• Hysterectomy: Definitive treatment for women with AUB who have completed childbearing and in whom conservative approaches have failed; associated with longer recovery and major surgery risks compared to hysteroscopy.